A healthy future for all
Our overarching aim is to make tomorrow’s world a healthier place – for everyone. Therefore, we are committed to using our scientific and technological innovation to improve the health of underserved populations in low- and middle-income countries. We strive to innovate, make health solutions affordable and accessible, as well as raise awareness about diseases, and help people learn how to manage them.
We are committed to eliminating schistosomiasis through an integrated approach which also favors scientific and technological innovation. We are working to improve diagnosis, increase disease control, expand access to healthcare, and strengthen local health systems. At the same time we are developing potential new treatment options, such as arpraziquantel, for millions of very young patients mainly in Africa.
Building scientific capacity where it is needed
Together with Seeding Labs, we are helping to expand access to STEM education and accelerate innovation in low- and middle-income countries by focusing on building capacity for the advancement of R&D. Above and beyond this, the knowledge-sharing platform helps reduce barriers to scientific exchange and strengthens global connections.
Seeding Labs provides institutions in low- and middle-income countries with resources to accelerate innovation and train young scientists.
Committed to health for all
At least half the world’s population does not have adequate access to healthcare - that’s why we've made it a high priority to address this global disparity. As part of our commitment to health for all, we will implement our Access Strategy to reach millions of patients in low- and middle-income countries.
I believe everyone – no matter where they live – should have access to optimal healthcare. Our commitment to patients drives us to go deeper, wider and faster to achieve access for all.
Stopping the spread of Schistosomiasis
is the number of tablets we donated for distribution in 2022 in 27 countries, 24 of which are in sub-Saharan Africa.
Treating school-aged children
is the number of tablets we have provided in partnership with WHO to treat schistosomiasis in 47 endemic African countries since 2007. 680 million school-aged children could be treated since.
is the estimated number of people we will provide with improved access to water supply and healthcare facilities in cooperation with the NALA Foundation by mid 2023. Since 2017, we have been supporting WASH (water, sanitation and hygiene) activities in Ethiopia.
An invisible enemy
We are working with global partners to eliminate schistosomiasis, a tropical worm disease. Providing tablets for treatment is crucial. In combination with innovation, greater awareness and access to clean, safe water, patients in endemic regions can be healthy and active members of their communities.
Thanks for supporting us in raising awareness of this important topic! Improving hygiene and sanitation is crucial in fighting this disease.
Our stories from the Sustainability Report 2021
Recent scientific research found the prevalence of schistosomiasis in school-aged children in sub-Saharan Africa fell nearly 60% between 2000-2019.
This huge reduction in schistosomiasis cases shows we are on the road to #makingSchistory!
I am proud that we provided tablets for 47 endemic African countries to help school-aged children.
Promising news for the youngest
Around 50 million preschool-aged children suffering from schistosomiasis don’t have access to treatment – but we are aiming to close this gap. In 2021, in partnership with the Pediatric Praziquantel Consortium, we reached an important development milestone for a new potential treatment option.
Congrats to the team on their achievement! The completion of the clinical Phase III trial brings hope to the most vulnerable populations affected by this devastating worm disease.
As part of our ambition to eliminate schistosomiasis, we are collaboratively defining a new model for sustainable and equitable access to health innovations for neglected tropical diseases.
Beatrice Greco, Global Health Institute, Switzerland
We are proud to work with our partners to expand access to schistosomiasis treatment for preschool-aged children, a key group largely excluded from historical control efforts.
Jennifer Burrill, Unlimit Health, UK